HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.

Abstract
Cilnidipine, an N/L-type calcium channel blocker, has been reported to inhibit sympathetic nerve activity and has a greater renoprotective effect than L-type calcium channel blockers. To investigate the hypothesis that cilnidipine might ameliorate advanced hypertensive nephropathy and inhibit the renal renin-angiotensin-aldosterone system, cilnidipine (1 mg per kg per day) or amlodipine (1 mg per kg per day) was administered to uninephrectomized deoxycorticosterone (DOCA)-salt hypertensive rats (DOCA-salt) for 4 weeks by gavage. Although the blood pressure in the DOCA-salt group was higher than that of control, neither cilnidipine nor amlodipine had any effect on the increase in blood pressure in the DOCA-salt group. The DOCA (40 mg per kg per week, subcutaneously (s.c.)) and salt (1% NaCl in drinking water) treatment significantly aggravated the levels of urinary protein excretion and creatinine clearance and increased glomerulosclerosis and collagen deposition in the tubulointerstitial area of the kidney. These effects were attenuated by cilnidipine treatment. Reverse transcription-polymerase chain reaction analysis revealed that the renal expression of mRNA for collagen I/IV and transforming growth factor-β was enhanced in the DOCA-salt group and that the overexpression of these molecules was suppressed by cilnidipine. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-derived superoxide production in the kidney and urinary norepinephrine excretion, which were enhanced in the DOCA-salt group, were suppressed by cilnidipine. Cilnidipine also decreased the activity and expression of angiotensin-converting enzyme (ACE) and the aldosterone concentration in the renal homogenate. Although neither cilnidipine nor amlodipine had any effect on the increased blood pressure in the DOCA-salt group, these renal changes were not induced by treatment with amlodipine. In conclusion, cilnidipine inhibited renal dysfunction, sympathetic nerve activity and renal renin-angiotensin-aldosterone system in the DOCA-salt group.
AuthorsHiroe Toba, Mamiko Yoshida, Chisato Tojo, Arisa Nakano, Yuko Oshima, Yushi Kojima, Kazuki Noda, Jiahong Wang, Miyuki Kobara, Tetsuo Nakata
JournalHypertension research : official journal of the Japanese Society of Hypertension (Hypertens Res) Vol. 34 Issue 4 Pg. 521-9 (Apr 2011) ISSN: 1348-4214 [Electronic] England
PMID21270815 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Calcium Channel Blockers
  • Calcium Channels, L-Type
  • Calcium Channels, N-Type
  • Dihydropyridines
  • Intracellular Signaling Peptides and Proteins
  • Membrane Proteins
  • NPHS2 protein
  • Transforming Growth Factor beta
  • Amlodipine
  • Desoxycorticosterone
  • Sodium Chloride
  • Collagen
  • cilnidipine
Topics
  • Amlodipine (pharmacology, therapeutic use)
  • Animals
  • Calcium Channel Blockers (pharmacology, therapeutic use)
  • Calcium Channels, L-Type (drug effects)
  • Calcium Channels, N-Type (drug effects)
  • Collagen (metabolism)
  • Desoxycorticosterone (adverse effects)
  • Dihydropyridines (pharmacology, therapeutic use)
  • Disease Models, Animal
  • Hypertension (chemically induced, drug therapy, physiopathology)
  • Intracellular Signaling Peptides and Proteins (metabolism)
  • Kidney (drug effects, metabolism, pathology)
  • Male
  • Membrane Proteins (metabolism)
  • Proteinuria (prevention & control)
  • Rats
  • Rats, Wistar
  • Renin-Angiotensin System (drug effects, physiology)
  • Sodium Chloride (adverse effects)
  • Transforming Growth Factor beta (metabolism)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: